Which peptides a pharmacy can legally compound in 2026

Which peptides can be compounded in 2026 is the first question a peptide brand founder asks, and the answer is less a list of molecules than a description of a process. A 503A pharmacy may compound with a bulk substance only if that substance is a component of an FDA-approved drug, has a USP or NF monograph, or appears on FDA's 503A bulk drug substances list. Most peptides sold online meet none of those tests. A brand's menu is therefore the FDA list plus whatever the state boards will tolerate, and it should be built to what a licensed 503A pharmacy can lawfully fill today, not to what a forum says works.

How the bulk drug substances list works

A 503A pharmacy is a state-licensed pharmacy that compounds for an identified patient on a prescription; the 503A compounding entry explains the category. Federal law gives such a pharmacy three routes to a lawful ingredient. The ingredient can be the active component of an approved drug. It can have a monograph in the United States Pharmacopeia or National Formulary. Or it can appear on the list of bulk drug substances FDA has approved for 503A use. Peptides on a typical wellness menu almost never satisfy the first two, which leaves the list.

The list itself is short and the queue to get on it is long. FDA publishes a working document of every substance that has been nominated, sorted into three categories. In the version updated May 14, 2026, FDA defines them as Category 1, bulk drug substances under evaluation; Category 2, bulk drug substances that raise significant safety risks; and Category 3, bulk drug substances nominated without adequate support. A nominated substance moves through FDA review, then to the Pharmacy Compounding Advisory Committee, the PCAC, for a nonbinding vote, then through notice-and-comment rulemaking before it lands on the final list or is formally excluded.

The category that matters for a pharmacy today is Category 1. Under FDA's interim policy on compounding with nominated bulk substances, the agency has said it does not intend to take action against a 503A pharmacy for using a Category 1 substance while evaluation is pending, provided the pharmacy meets the other conditions of section 503A, including sourcing from an FDA-registered supplier with a certificate of analysis. That is enforcement discretion, not approval, and it does not extend to Category 2 or Category 3. A substance in neither Category 1 nor the final list has no federal basis for compounding at all.

Category 1: what a pharmacy can fill today

Read FDA's May 14, 2026 document and the Category 1 entries relevant to a peptide or longevity menu are few. GHK-Cu appears, but only for non-injectable routes of administration. Glutathione, which is a tripeptide, appears. Nicotinamide adenine dinucleotide, listed as NAD, and its reduced form NADH appear. Vasoactive intestinal peptide appears. Enclomiphene citrate, melatonin, methylcobalamin and pregnenolone are on the same page, which is why so many peptide menus are really mixed wellness menus running under the same rules.

The GHK-Cu entry carries a note that shows how fragile Category 1 status is. According to that note, GHK-Cu was removed from Category 1 on April 22, 2026 because its nominators withdrew their nominations. On May 5, 2026, one nominator clarified that it meant to withdraw only the injectable route and wished to keep its nomination for non-injectable routes, so FDA restored GHK-Cu, except for injectable administration, to Category 1 and said it intends to consult PCAC on it before the end of February 2027. A pharmacy compounding injectable GHK-Cu after April 22 was compounding a substance in no category at all.

Just as important is what does not appear in Category 1 on that document. BPC-157, TB-500, CJC-1295, ipamorelin, tesamorelin, AOD-9604, semax, selank, epitalon, MOTS-c and KPV are not listed there. Some of them are in no category at all as of May 14, 2026. A brand that has seen those names on a competitor's menu should not conclude that a pharmacy somewhere has found a basis for them; it should conclude that somebody is taking a risk, and ask who.

Category 2: substances a pharmacy cannot use

Category 2 on the May 14, 2026 document is six entries: cesium chloride, domperidone, germanium sesquioxide, ibutamoren mesylate, kisspeptin-10, and quinacrine hydrochloride for intrauterine administration. Two of those sit on peptide menus. Kisspeptin-10 is a peptide. Ibutamoren, sold as MK-677, is an oral growth-hormone secretagogue that is not a peptide but is marketed beside them. FDA keeps a separate page summarizing the safety risks it identified for each, and the interim policy provides no enforcement discretion for any of them.

Category 3 is easy to overlook and deserves a glance, because absence from Category 2 is not the same as permission. On the same document, GHRP-2, GHRP-6, mechano growth factor, cibinetide (ARA-290) and thymulin acetate sit in Category 3, nominated without adequate support. A Category 3 substance is not under evaluation, has no enforcement discretion, and will not move until someone files a nomination FDA considers adequate. From a pharmacy's point of view, Category 2 and Category 3 lead to the same place.

The April 2026 removals and what pending means

Law-firm regulatory alerts reported that in April 2026 FDA removed BPC-157 and a group of other peptides from Category 2, where several had sat since FDA's 2023 safety review. FDA's own document, updated May 14, 2026, is consistent with that: BPC-157 no longer appears in Category 2, and the Category 2 heading points readers to a separate page covering substances previously in Category 2 that were withdrawn. What the removal did not do is place those peptides in Category 1. On the May 14 document, BPC-157 appears in no category. It is out of the safety-risk box and not yet in the under-evaluation box.

The evaluation happened in public on July 23 and 24, 2026, when FDA convened the PCAC, per the meeting notice on FDA's advisory committee calendar. FDA's own briefing position, per that notice, was that BPC-157 in both free-base and acetate form should not be included on the 503A bulks list. The committee disagreed on most of the slate. As AJMC reported, the committee voted 8 to 6 with one abstention in favor of BPC-157, KPV and TB-500; 7 to 5 with two abstentions in favor of MOTS-c; supported semax and epitalon by similarly tight margins; and voted down emideltide 7 to 6 with one abstention.

Those votes are advisory. AJMC's report put it plainly: none of the peptides have been added to the 503A bulks list, and FDA must decide whether to accept the recommendations and then run notice-and-comment rulemaking, a proposed rule, a comment period and a final rule, before a pharmacy could lawfully compound them. That is what pending means. A substance can be endorsed by a committee, absent from Category 2, and still have no basis for compounding. FDA's stated position going into the meeting was against inclusion, and the agency is not bound to change its mind because a vote went 8 to 6.

A substance can be endorsed by a committee, absent from Category 2, and still have no basis for compounding.

For an operator, the working rule is simple. A peptide that is on the final 503A list, or in Category 1 with the route the pharmacy uses, can go on the menu. A peptide that is pending in any other sense stays off it until the Federal Register says otherwise, however encouraging the committee transcript reads.

Research-use-only sales are not a workaround

The other supply operators encounter is the vial labeled for research use only, sold online with a wink. That label exists for laboratory reagents that will never touch a person. Selling such a product to consumers, with content or context that implies human use, is marketing an unapproved drug, and law-firm alerts report that FDA sent warning letters to online peptide sellers in March and April 2026 on exactly that basis. A brand that links to such a seller, or whose providers suggest patients find product there, has joined the seller's chain of distribution while adding a medical licence to the case file.

The commercial consequences arrive before the legal ones. Ad platforms will not run the campaign: Google's policy requires certification for telemedicine providers running prescription-drug ads, and LegitScript, whose certification Google, Meta, Microsoft and TikTok recognize per its own site, does not certify operations dispensing unapproved product. Payment processors read the same signals. A peptide brand that cannot advertise, cannot process cards and cannot be certified has a menu, not a business.

What state boards are enforcing

Federal categories set the outer edge. State boards of pharmacy and state medical boards do the enforcement a brand will actually meet, and the pattern across boards is consistent even where the rules differ. Pharmacy inspectors check each compounded substance against the three statutory routes and ask the pharmacy to show which one it is relying on. They ask for the supplier's FDA registration and a certificate of analysis per lot. For injectables, they ask for the sterile compounding permit, and for a nonresident pharmacy, the licence for the patient's state.

Medical boards approach the same file from the prescriber's side. Prescribing a substance with no lawful compounding basis, or directing a patient to research-grade product, is a standard-of-care question and a licence question. Med spas and clinics that hold vials on site and hand them to patients without a pharmacy in the chain are a recurring target, because dispensing without a pharmacy licence is its own offense in most states. Specific state rules vary, and the states index covers telehealth rules state by state; the point for a peptide brand is that every link in the chain, prescriber, pharmacy and storefront, has a regulator who can read the FDA document.

Building a menu to what a pharmacy can fill

The menu-building method that survives inspection starts from the FDA document as it reads on the day the menu is built, not from a competitor's site. For each substance, the pharmacy states in writing which statutory route it relies on: approved-drug component, USP or NF monograph, or Category 1 with the route of administration noted. Anything it cannot place is off the menu. The menu gets rechecked against the FDA document on a schedule, because substances leave Category 1 with a two-line note and no press release, as GHK-Cu did in April.

Sermorelin is the example operators raise most, and it illustrates the first route. It was once the active ingredient of an FDA-approved product, and pharmacies that compound it rely on that pathway rather than on the bulks list. Whether a particular pharmacy's sourcing and use fit that pathway is a question for the pharmacy's regulatory counsel, and the brand should have the answer in writing before the substance appears on a storefront. The same discipline applies to any peptide a pharmacy describes as grandfathered, established, or widely compounded; none of those words is one of the three routes.

Tessic Health's peptide clinics are built this way. The pharmacy network fills only substances with a documented 503A basis, the menu is reviewed against FDA's bulk drug substances document, and providers licensed in all 50 states prescribe within it. Medication passes through at 0% markup, so no one in the chain earns more by stretching a gray-area substance onto the list. The peptide brand launch guide and the peptides launch page cover the rest of the setup.

Questions operators ask

Is BPC-157 legal to compound? As of this writing it is not on the 503A bulks list and not in Category 1. The PCAC voted in its favor in July 2026, per AJMC, and FDA's stated position going into that meeting was against inclusion. Until a final rule adds it to the list, a 503A pharmacy has no documented basis for it, whatever the vote count.

Can a 503B outsourcing facility make the peptides a 503A pharmacy cannot? The 503B route runs on its own bulks list with its own categories, and a 503B facility also needs the substance to appear there. A 503B label does not create a basis that the 503A list lacks; it changes which list to check.

Is topical or oral GHK-Cu fine when injectable is not? On the May 14, 2026 document, GHK-Cu sits in Category 1 for non-injectable routes only, with PCAC review expected before the end of February 2027. A pharmacy can rely on the interim policy for a non-injectable preparation and cannot for an injectable one.

Does NAD count as a peptide? It does not, but it is in Category 1 on the FDA document, and it sits on most peptide menus. The framework is the same for every substance: which route, which category, which route of administration, and who put it in writing.

Do the July votes mean the menu can expand in 2027? Possibly. FDA has to act on the recommendations and publish a proposed rule first, and it has committed only to consulting PCAC on GHK-Cu before the end of February 2027. The Federal Register, not a vendor newsletter, is where the answer will appear.

A peptide brand built in 2026 runs on a shorter menu than the market suggests. The menu is defensible, it can be advertised, and it will still exist after the next inspection. That is worth more than any single molecule.